Brief: Plx Pharma Receives FDA Approval Of SNDAs For Both Vazalore 325 Mg And 81 Mg
01/03/2021 14:06
March 1 (Reuters) - PLx Pharma Inc PLXP.O :
* PLX PHARMA RECEIVES FDA APPROVAL OF SNDAS FOR BOTH
VAZALORE 325
MG AND 81 MG
* PLX PHARMA INC - U.S. COMMERCIAL LAUNCH OF VAZALORE
PLANNED FOR
Q3 2021
Source text for Eikon: ID:nGNX4GNQrV
Further company coverage: PLXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PLx Pharma Winddown
See all newsAustralia's Pilbara Minerals jumps on Pilgangoora lithium resource upgrade
Brief: Plx Pharma Winddown Terminated Employment Of Natasha Giordano, President And CEO, And Rita O'connor, CFO
Brief: PLx Pharma Inc. Enters Into A Stalking Horse Asset Purchase Agreement To Sell Vazalore And Substantially All Of Its Assets
U.S. STOCKS ON THE MOVE-HeartCore, Freight Technologies, MongoDB
Brief: Plx Pharma Inc. Receives Nasdaq Delisting Notice